STAT9h
Pharmalittle: We’re reading about an Alzheimer’s drug about-face, Bavarian Nordic’s views on Trump, and more
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Business Insider17h
Positive EMA Reversal Boosts Biogen’s Leqembi Prospects Despite Challenges
Analyst Michael Yee of Jefferies maintained a Buy rating on Biogen (BIIB – Research Report), retaining the price target of $250.00. Michael Yee has given his Buy rating due to a combination of factors ...